New 'Living Drug' trial targets Tough-to-Treat blood cancer
NCT ID NCT06281847
Summary
This early-stage trial is testing a new type of treatment called CCTx-001 for adults with acute myeloid leukemia (AML) that has come back or hasn't responded to other therapies. CCTx-001 is a CAR-T cell therapy, which involves modifying a patient's own immune cells to target and attack the leukemia cells. The study will first find the safest and most effective dose, then see how well the treatment works at controlling the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA REFRACTORY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Besançon Regional and University Hospital
Besançon, France
Contact
Contact
-
Hospital Saint Louis
Paris, France
Contact
Contact
-
Karolinska University Hospital
Stockholm, Sweden
Contact
Contact
-
Ludwig-Maximilians University of Munich
Munich, Germany
Contact
Contact
-
University Hospital Ulm
Ulm, Germany
Contact
Contact
-
Vall d'Hebron University Hospital
Barcelona, Spain
Contact
Contact
Conditions
Explore the condition pages connected to this study.